Catalio Capital Management, LP Blueprint Medicines Corp Transaction History
Catalio Capital Management, LP
- $457 Billion
- Q4 2024
A detailed history of Catalio Capital Management, LP transactions in Blueprint Medicines Corp stock. As of the latest transaction made, Catalio Capital Management, LP holds 284,654 shares of BPMC stock, worth $26.7 Million. This represents 5.43% of its overall portfolio holdings.
Number of Shares
284,654Holding current value
$26.7 Million% of portfolio
5.43%Shares
1 transactions
Others Institutions Holding BPMC
# of Institutions
373Shares Held
65.1MCall Options Held
2.25MPut Options Held
1.01M-
Vanguard Group Inc Valley Forge, PA6.77MShares$636 Million0.01% of portfolio
-
Black Rock Inc. New York, NY6.65MShares$624 Million0.02% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD5.68MShares$533 Million0.06% of portfolio
-
Wellington Management Group LLP Boston, MA4.28MShares$402 Million0.07% of portfolio
-
State Street Corp Boston, MA2.5MShares$235 Million0.01% of portfolio
About Blueprint Medicines Corp
- Ticker BPMC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,719,600
- Market Cap $5.61B
- Description
- Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...